Picture of Relay Therapeutics logo

RLAY Relay Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Relay Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview

* Relay Therapeutics Inc  RLAY.OQ   RLAY.O  is expected
to show a
rise in quarterly revenue when it reports  results on August 2
(estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 104.9% increase in revenue to $747.78 thousand from $365
thousand a year ago, according to the mean estimate from 9
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Relay Therapeutics
Inc is
for a loss of 81 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Relay
Therapeutics Inc is $29​, above​ its last closing price
of $12.60. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.66       -0.69      -0.78     Missed  -12.8
 Dec. 31 2023  -0.71       -0.70      -0.56     Beat    20.3
 Sep. 30 2022  -0.72       -0.71      -0.76     Missed  -7.7​
 Jun. 30 2022  -0.63       -0.63      -0.71     Missed  -13
 ​​Mar.        -0.62       -0.62      -0.57     Beat    7.8
 31 2022                                                
 Dec. 31 2021  -0.57       -0.58      -0.62     Missed  -7.2​
 Sep. 30 2021  -0.65       -0.64      -0.66     Missed  -3.4
 Jun. 30 2021  -0.44       -0.46      -2.10     Missed  -360.8
 This summary was machine generated August 1 at 01:23 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Relay Therapeutics

See all news